BioCryst is constantly seeking to expand and improve its therapeutic development pipeline. It utilizes strategic partnerships early in the drug identification process through in-licensing of drug targets. BioCryst has also established collaborative relationships for the development and commercialization of product candidates to expand its geographic reach beyond the United States.
If you are interested in contacting BioCryst regarding partnering opportunities, please email the Business Development team at: businessdevelopment@BioCryst.com.
Torii Pharmaceutical, Co.
In November 2019, BioCryst announced that it had licensed commercialization rights in Japan to Torii Pharmaceutical, Co. for ORLADEYO® (berotralstat).
In June 2021, BioCryst and Neopharm Ltd. in Israel entered into a distribution and supply agreement granting exclusive rights to commercialize ORLADEYO in Israel. Neopharm Ltd. is one of the leading pharmaceutical companies in Israel, providing the Israeli market with a wide range of products and integrated services.
In September 2021, BioCryst and NewBridge Pharmaceuticals entered into a distribution and supply agreement to commercialize ORLADEYO in the Gulf Cooperation Council (GCC) and Iraq. NewBridge is a regional specialty company with a comprehensive pharmaceutical platform of services and expertise established to bridge the access gap and partner with global pharma and biotech companies to in-license and commercialize FDA or EMA approved innovative therapeutics that address unmet medical needs into the Middle East and North Africa (MENA) regions.
In June 2022, BioCryst and Pint Pharma entered into a distribution and supply agreement to commercialize ORLADEYO in Latin America. Pint Pharma is an Austria-based pharmaceutical company that has extensive experience developing, registering and commercializing rare disease and specialty treatments throughout Latin America.
RAPIVAB® (peramivir injection)
Shionogi & Co., Ltd.
In March 2007, BioCryst entered into an exclusive license agreement to develop and commercialize peramivir in Japan and Taiwan. An intravenous formulation of peramivir has been marketed under the commercial name RAPIACTA® since 2010.
Green Cross Corporation
In June 2006, BioCryst and Green Cross Corp. entered into an agreement to develop and commercialize peramivir in Korea. Green Cross Corp. announced in August 2010 that it had received marketing and manufacturing authorization for IV peramivir in Korea.
In November 2011, BioCryst and Mundipharma amended their 2006 licensing agreement to grant Mundipharma exclusive worldwide rights to develop and commercialize forodesine.
The University of Alabama at Birmingham
Albert Einstein College of Medicine of Yeshiva University